Innovative therapeutics

Investors

SEC Filings

NASDAQBMRN
FormDescriptionDateFormat
SC 13GSchedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutionsMar 10, 2010View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesMar 10, 2010View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesMar 10, 2010View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesMar 8, 2010View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesMar 5, 2010View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesMar 3, 2010View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesMar 3, 2010View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesMar 1, 2010View HTMLDownload DOCDownload PDF
10-KAnnual report which provides a comprehensive overview of the company for the past yearFeb 26, 2010View HTMLDownload DOCDownload PDFDownload XLS
5Annual filing director officer or owner of more than ten percent.Feb 25, 2010View HTMLDownload DOCDownload PDF
5Annual filing director officer or owner of more than ten percent.Feb 25, 2010View HTMLDownload DOCDownload PDF
8-KReport of unscheduled material events or corporate eventFeb 23, 2010View HTMLDownload DOCDownload PDFDownload XLS
SC 13G/AAmendment to a previously filed SC 13GFeb 16, 2010View HTMLDownload DOCDownload PDFDownload XLS
SC 13G/AAmendment to a previously filed SC 13GFeb 12, 2010View HTMLDownload DOCDownload PDF
SC 13G/AAmendment to a previously filed SC 13GFeb 11, 2010View HTMLDownload DOCDownload PDFDownload XLS
SC 13G/AAmendment to a previously filed SC 13GFeb 8, 2010View HTMLDownload DOCDownload PDFDownload XLS
4Statement of changes in beneficial ownership of securitiesFeb 5, 2010View HTMLDownload DOCDownload PDF
8-KReport of unscheduled material events or corporate eventFeb 5, 2010View HTMLDownload DOCDownload PDFDownload XLS
SC 13GSchedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutionsFeb 4, 2010View HTMLDownload DOCDownload PDFDownload XLS
4Statement of changes in beneficial ownership of securitiesJan 27, 2010View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesJan 25, 2010View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesJan 21, 2010View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesJan 21, 2010View HTMLDownload DOCDownload PDF
1-25      26-50      51-75      76-100      101-123

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

Palynziq™
Brineura™
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information